Q-omics provides the consensus-scored TASOR profile across patient tissues and cancer cell-line models. TASOR expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TASOR is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, TASOR RNA expression shows 21,261 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LIHC, and ACC as cancer lineages where TASOR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TASOR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TASOR survival associations across molecular data types. TASOR RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TASOR RNA expression–survival associations across cancer types. High TASOR expression shows unfavorable associations in KICH, ACC and LIHC, but favorable associations in BRCA, SKCM and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for TASOR RNA expression.
This table summarizes TASOR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TASOR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TASOR shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, KIRP, CHOL and STAD. The LIHC box plot shows higher TASOR RNA expression in tumor versus normal tissue (log2 FC = +1.078, t-test p < 0.001).
This table shows molecular features associated with TASOR in patient tissues and cancer cell lines. In patient samples, TASOR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TASOR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
